Skip to main content
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 2004 Mar;42(3):1333–1336. doi: 10.1128/JCM.42.3.1333-1336.2004

A Canine Parvovirus Mutant Is Spreading in Italy

Vito Martella 1,*, Alessandra Cavalli 1, Annamaria Pratelli 1, Giancarlo Bozzo 1, Michele Camero 1, Domenico Buonavoglia 2, Donato Narcisi 1, Maria Tempesta 1, Canio Buonavoglia 1
PMCID: PMC356904  PMID: 15004112

Abstract

By antigenic and genetic characterization of canine parvovirus type 2 (CPV-2) strains collected in 2001 and 2002 in Italy, it was possible to observe the spread of viruses with an unusual mutation, Glu-426, affecting a major antigenic epitope of CPV-2. Out of 67 strains analyzed, 49 (73.13%) were characterized as CPV-2a, 6 (8.95%) were characterized as CPV-2b, and 12 (17.91%) were characterized as the Glu-426 mutant.


In the early 1970s, a new infectious disease with a high rate of mortality was observed in pups throughout the world, and a novel parvovirus was isolated in both canine and feline cell cultures (2, 7, 14, 15). The virus was referred to as canine parvovirus type 2 (CPV-2) to distinguish it from the unrelated parvovirus minute virus of canines (MVC or CPV-1) (8, 9).

CPV-2 possesses a single-stranded DNA genome of about 5,200 nucleotides in length, enclosed in a 26-nm-diameter icosahedral capsid made up of a combination of two proteins, VP1 and VP2 (1, 25). By sequence analysis, CPV-2 has been shown to be closely related to feline panleukopenia virus, from which it presumably originated, and also to parvoviruses from raccoons, minks, and arctic foxes, all of which are included in the feline parvovirus subgroup (20, 33). A few years after the emergence of CPV-2, two new antigenic types, designated type 2a and type 2b and distinguishable by means of monoclonal antibodies (MAbs), arose consecutively (21, 23). Currently, the antigenic variants of CPV have completely replaced the original type 2 virus and are variously distributed in canine populations worldwide (2, 4, 11, 12, 15, 24, 26, 28, 29, 32, 34).

Following the onset and rapid spread of the antigenic variants CPV-2a and CPV-2b, there has been little evidence for a further significant evolution, even if some unusual mutations, such as 300-Asp or 265-Pro, have been described sporadically and another mutation, Ala-297, is now detectable in most of the recent CPV strains irrespective of their antigenic type and geographical origin (3, 13, 29, 32, 34).

Analysis of CPV strains detected in Italy revealed the onset in 2000 of an unusual CPV-2 mutant (5), with a change (Asp-426 to Glu) occurring in the strategic residue 426 (1, 21, 30) (Table 1). The mutation, although affecting an important antigenic epitope of CPV-2, is not identifiable by a panel of MAbs used commonly to characterize CPV strains antigenically, as the Glu-426 mutant displays the same monoclonal reactivity as CPV-2b (5), i.e., they are not recognized by MAb B4A2 (Table 2). However, since the nucleotide variation responsible for the substitution Asp-426 or Asn-426 to Glu at nucleotide 4064 created a new MboII restriction site (GAAGA) unique to these strains, it is possible to distinguish easily the Glu-426 mutants from other antigenic types by restriction enzyme analysis (5).

TABLE 1.

Amino acid changes in the VP2 capsid protein of reference parvoviruses of the feline subgroupa

Virus type Country of origin, year of isolation Strain Source animal Amino acid changes at residue:
87 101 265 297 300 305 426 555
FPV U.S., 1967 FPV-b Cat Met Ile Thr Ser Ala Asp Asn Val
MEV U.S., 1975 MEV-b Mink Met Ile Thr Ser Val Asp Asn Val
CPV-2 U.S., 1978 CPV-b Dog Met Ile Thr Ser Ala Asp Asn Val
U.S., 1978 CPV-Norden Dog Met Ile Thr Ser Ala Asp Asn Val
CPV-2a U.S., 1984 CPV-15 Dog Leu Thr Thr Ser Gly Tyr Asn Ile
U.S., 1983 CPV-31 Dog Leu Thr Thr Ser Gly Tyr Asn Ile
CPV-2b U.S., 1984 CPV-39 Dog Leu Thr Thr Ser Gly Tyr Asp Val
U.S., 1990 CPV-133 Dog Leu Thr Thr Ser Gly Tyr Asp Val
Asp-300 CPV-2 Vietnam, 2000 LCPV-V203 Leopard Leu Thr Thr Ala Asp Tyr Asp Val
Vietnam, 2000 LCPV-V140 Leopard Leu Thr Thr Ala Asp Tyr Asn Val
Pro-265 CPV-2 Italy, 2000 CPV-616 Dog Leu Thr Pro Ser Gly Tyr Asp Val
Italy, 2000 W42 Wolf Leu Thr Pro Ser Gly Tyr Asp Val
Glu-426 CPV-2 Italy, 2000 136/00 Dog Leu Thr Thr Ala Gly Tyr Glu Val
Italy, 2000 56/00 Dog Leu Thr Thr Ala Gly Tyr Glu Val
a

Recently identified patrovirus mutants are shown in bold.

TABLE 2.

Reactivities of MAbs against CPV-2, CPV-2a, CPV-2b, and the Glu-426 CPV-2 mutants by hemagglutination inhibition

Isolate Reactivities of MAbsa
Antigenic type, amino acid change
A4E3 B4A2 C1D1 B4E1
DP/83 160 160 0 1,280 CPV-2, Asn-426
188-01 (B) 640 80-160 1,280 40 CPV-2a, Asn-426
108-02 (44) 640 80-160 2,560 20-40 CPV-2a, Asn-426
119-02 (A) 640 80 1,280 20-40 CPV-2a, Asn-426
42-01 2,560 0 2,560 20-40 CPV-2b, Asp-426
198-02 (A) 640 0 1,280 0 CPV-2b, Asp-426
205-02 1,280 20 1,280 10 CPV-2b, Asp-426
56-00 320 0 1,280 20 CPV-2?, Glu-426
136-00 1,280-2,560 5-10 2,560 20 CPV-2?, Glu-426
157-02 (5) 320 0 640-1,280 20-40 CPV-2?, Glu-426
202-02 (1) 160 0 640 20 CPV-2?, Glu-426
202-02 (1) 160 0 640 20 CPV-2?, Glu-426
a

Values indicate the reciprocal of the highest dilution of MAb inhibiting eight hemagglutination units of the virus. MAb specificities are as follows: A4E3 for CPV-2, CPV-2a, and CPV-2b; B4A2 for CPV-2 and CPV-2a; C1D1 for CPV-2a and CPV-2b; and B4E1 for CPV-2.

By combining antigenic and genetic analyses, searches for CPVs displaying the Glu-426 mutation were conducted in different parts of Italy (Apulia, Sicily, and Campania) between 2001 and 2002. A total of 67 CPV strains were detected by a hemagglutination assay in either specimens or rectal swabs of pups affected by gastroenteritis. Attempts to adapt the CPV strains to in vitro cultivation in A-72 cells were made. The viruses identified underwent antigenic characterization in a hemagglutination inhibition assay using a panel of four MAbs (A4E3, B4A2, C1D1, and B4E1), kindly supplied by C. R. Parrish (Cornell University, Ithaca, N.Y.). The differential reactivity of CPV-2, CPV-2a, and CPV-2b to MAbs is shown in Table 2. All the strains characterized as type 2b by MAb analysis were subjected to genetic screening by restriction enzyme analysis. The PCR product generated with the primer pair 555for-555rev, corresponding to the COOH terminus of CPV open reading frame 2, was digested with the restriction enzyme MboII (5). To verify the accuracy of MboII digestion, the amplicons 555for-555rev were directly sequenced by using a BigDye sequencing kit and an ABI-377 automatic DNA sequencer (Applied Biosystems, Foster City, Calif.).

In 2001 and 2002, type 2a was the most common antigenic type. Three type 2b CPVs were detected in 2001 and three were detected in 2002. Although in 2000 only two Glu-426 strains had been detected, three strains in 2001 and nine strains in 2002 were identified (Table 3). It is of note that the Glu-426 strains were detected in different areas of southern Italy (Apulia, Sicily, and Campania). Sequence analysis of the strains identified as the Glu-426 mutant by MboII digestion confirmed the presence of the mutation T→A at nucleotide 4064 (data not shown).

TABLE 3.

Antigenic and genetic characterization of CPV-2 strains in Italya

Antigenic type MboII site (nt 4062-4066) Origin of the strain Yr of isolation
CPV-2a
    4-01 Abruzzo 2001
    41-01 Apulia 2001
    52-01 Apulia 2001
    57-01 Apulia 2001
    62-01 Apulia 2001
    70-01 (A) Apulia 2001
    77-01 Apulia 2001
    85-01 Apulia 2001
    89-01 (B) Apulia 2001
    91-01 (D) Apulia 2001
    93-01 (A) Apulia 2001
    93-01 (B) Apulia 2001
    96-01 Apulia 2001
    97-01 (B) Apulia 2001
    98-01 (A) Apulia 2001
    99-01 Apulia 2001
    102-01 (C) Apulia 2001
    102-01 (A) Apulia 2001
    104-01 (A) Apulia 2001
    106-01 Apulia 2001
    111-01 (B) Apulia 2001
    113-01 Apulia 2001
    120-01 Apulia 2001
    122-01 Apulia 2001
    146-01 Apulia 2001
    169-01 Apulia 2001
    184-01 (A) Apulia 2001
    188-01 (B) Apulia 2001
    228-01 Apulia 2001
    233-01 Apulia 2001
    239-01 (A) Apulia 2001
    255-01 (A) Apulia 2001
    273-01 (I) Apulia 2001
    273-01 (2) Apulia 2001
    288-01 Apulia 2001
    297-01 (A) Apulia 2001
    307-01 (A) Apulia 2001
    307-01 (B) Apulia 2001
    2-02 Apulia 2002
    63-02 Apulia 2002
    69-02 Apulia 2002
    95-02 (A) Apulia 2002
    108-02 (8) Abruzzo 2002
    108-02 (32) Abruzzo 2002
    108-02 (44) Abruzzo 2002
    119-02 (A) Apulia 2002
    133-02 Apulia 2002
    146-02 Apulia 2002
    202-02 (3) Apulia 2002
CPV-2b
    42-01 No Apulia 2001
    281-01 (A) No Apulia 2001
    281-01 (B) No Apulia 2001
    61/02 No Apulia 2001
    198-02 (A) No Apulia 2002
    205-02 No Apulia 2002
    56-00 Yes Apulia 2000
    136-00 Yes Apulia 2000
    161-01 Yes Apulia 2001
    189-01 (3) Yes Sicily 2001
    189-01 (5) Yes Sicily 2001
    125-02 (debbi) Yes Campania 2002
    125-02 (leti) Yes Campania 2002
    157-02 (2) Yes Apulia 2002
    157-02 (5) Yes Apulia 2002
    157-02 (5-bis) Yes Apulia 2002
    202-02 (1) Yes Apulia 2002
    202-02 (2) Yes Apulia 2002
    231-02 (1) Yes Sicily 2002
    231-02 (2) Yes Sicily 2002
a

The Glu-426 CPV-2 mutants are boldfaced. nt, nucleotides.

An intriguing question arising from the initial identification of strains 56/00 and 136/00 was whether they represented a newly emerging variant of CPV or a natural mutant detected occasionally. The antigenic variants type 2a and type 2b totally replaced the original CPV-2 and now coexist, even if with different distributions in different countries. In Italy, CPV-2a is prevalent and CPV-2b is isolated with a low frequency (4, 6, 26). The findings of the present study demonstrate that these atypical 56/00- and 136/00-like CPVs are currently cocirculating in Italy together with the other CPV antigenic types.

A peculiarity of parvoviruses of the feline subgroup is that single nucleotide substitutions may determine drastic phenotypic changes affecting antigenicity, host range in vivo and in vitro, and hemagglutination (10, 13, 17, 21, 22, 27, 31, 33). The trajectory of CPV evolution may be considered as a paradigm of how viruses evolve. During its multistep process of evolution, CPV changed its antigenic profile, gained the ability to infect dogs, and lost and regained the ability to infect cats by changing a few amino acid residues (10, 13, 16, 18, 19, 20, 21, 33, 34). From this perspective, the appearance of new variants of CPV-2 as a result of the acquisition of additional changes represents a constant threat to domestic dogs. In recent years, some other CPVs with natural mutations, such as Asp-300 (13) and Pro-265 (3), that significantly affect either the antigenicity or the capsid structure have been identified, but there is no evidence for a further spread of these mutants. In contrast, evidence has now been collected that the Glu-426 mutant of CPV-2 is broadly present in both southern and northern Italy (4). It is therefore possible to speculate that the mutation at residue 426, within an immunodominant epitope of CPV (10, 18, 21, 30), has provided the mutant with a certain benefit.

Continued epidemiological surveillance of the distribution of the CPV types will help elucidate whether this mutant has become permanently established in the dog population and whether it is also spreading in other parts of the world, thus providing insights into the mechanisms driving the evolution of CPV-2.

Acknowledgments

This work was supported by grants from CEGBA (Centro di Eccellenza di Genomica in campo Biomedico ed Agrario) and from MURST (project “Enteriti dei piccoli animali,” Ministero dell'Università per la Ricerca Scientifica e Tecnologica).

We thank Paola Fiorente for expert technical assistance and Athina Papa for editorial suggestions. We are extremely grateful to Leland Eugene Carmichael for constant encouragement throughout the study.

REFERENCES

  • 1.Agbandje, M., C. R. Parrish, and M. G. Rossmann. 1995. The recognition of parvovirus capsids by antibodies. Semin. Virol. 6:219-231. [Google Scholar]
  • 2.Appel, M. J. G., W. F. Scott, and L. E. Carmichael. 1979. Isolation and immunization studies of canine parvo-like virus from dogs with haemorrhagic enteritis. Vet. Rec. 105:156-159. [DOI] [PubMed] [Google Scholar]
  • 3.Battilani, M., A. Scagliarini, E. Tisato, C. Turilli, I. Jacoboni, R. Casadio, and S. Prosperi S. 2001. Analysis of canine parvovirus sequences from wolves and dogs isolated in Italy. J. Gen. Virol. 82:1555-1560. [DOI] [PubMed] [Google Scholar]
  • 4.Battilani, M., and S. Prosperi. 2002. Parvovirus del cane: studio molecolare di alcuni ceppi del tipo 2 (CPV-2). Veterinaria 16:65-71. [Google Scholar]
  • 5.Buonavoglia, C., V. Martella, A. Pratelli, M. Tempesta, A. Cavalli, D. Buonavoglia, G. Bozzo, G. Elia, N. Decaro, and L. E. Carmichael. 2001. Evidence for evolution of canine parvovirus type-2 in Italy. J. Gen. Virol. 82:3021-3025. [DOI] [PubMed] [Google Scholar]
  • 6.Buonavoglia, D., A. Cavalli, A. Pratelli, V. Martella, G. Greco, M. Tempesta, and C. Buonavoglia. 2000. Antigenic analysis of canine parvovirus strains isolated in Italy. New Microbiol. 23:93-96. [PubMed] [Google Scholar]
  • 7.Burtonboy, G., F. Coignoul, P. P. Pastoret, and N. Delferriere. 1979. Canine hemorrhagic enteritis detection of viral particles by electron microscopy. Arch. Virol. 61:1-11. [DOI] [PubMed] [Google Scholar]
  • 8.Carmichael, L. E., and L. N. Binn. 1981. New enteric diseases in the dog. Adv. Vet. Sci. Comp. Med. 25:1-37. [PubMed] [Google Scholar]
  • 9.Carmichael, L. E., D. H. Schlafler, and A. Hashimoto. 1994. Minute virus of canines (MVC, canine parvovirus type-1): pathogenicity for pups and seroprevalence estimate. J. Vet. Diagn. Investig. 6:165-174. [DOI] [PubMed] [Google Scholar]
  • 10.Chang, S.-F., J.-Y. Sgro, and C. R. Parrish. 1992. Multiple amino acids in the capsid structure of canine parvovirus coordinately determine the canine host range and specific antigenic and hemagglutination properties. J. Virol. 66:6858-6867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.De Ybanez, R. R., C. Vela, E. Cortes, I. Simarro, and J. I. Casal. 1995. Identification of types of canine parvovirus circulating in Spain. Vet. Rec. 136:174-175. [DOI] [PubMed] [Google Scholar]
  • 12.Greenwood, N. M., W. S. K. Chalmers, W. Baxendale, and H. Thompson. 1996. Comparison of isolates of canine parvovirus by monoclonal antibody and restriction enzyme-analysis. Vet. Rec. 138:495-496. [DOI] [PubMed] [Google Scholar]
  • 13.Ikeda, Y., M. Mochizuki, R. Naito, K. Nakamura, T. Miyazawa, T. Mikami, and E. Takahashi. 2000. Predominance of canine parvovirus (CPV) in unvaccinated cat populations and emergence of new antigenic types of CPVs in cats. Virology 278:13-19. [DOI] [PubMed] [Google Scholar]
  • 14.Johnson, R. H., and P. B. Spradbrow. 1979. Isolation from dogs with severe enteritis of a parvovirus related to feline panleukopaenia virus. Aust. Vet. J. 55:151. [Google Scholar]
  • 15.Kelly, W. R. 1978. An enteric disease of dogs resembling feline panleukopaenia virus. Aust. Vet. J. 54:593. [DOI] [PubMed] [Google Scholar]
  • 16.Llamas-Sainz, A., M. Agbadje-McKenna, J. S. L. Parker, A. T. M. Wahid, C. R. Parrish, and M. G. Rossmann. 1996. Structural analysis of a mutation in canine parvovirus which controls antigenicity and host range. Virology 225:65-71. [DOI] [PubMed] [Google Scholar]
  • 17.Mochizuki, M., R. Harasawa, and H. Nakatani. 1993. Antigenic and genomic variabilities among recently prevalent parvoviruses of canine and feline origin in Japan. Vet. Microbiol. 38:1-10. [DOI] [PubMed] [Google Scholar]
  • 18.Parker, J. S. L., and C. R. Parrish. 1997. Canine parvovirus host range is determined by the specific conformation of an additional region of the capsid. J. Virol. 71:9214-9222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Parrish, C. R. 1991. Mapping specific functions in the capsid structure of canine parvovirus and feline panleukopenia virus using infectious plasmid clones. Virology 183:195-205. [DOI] [PubMed] [Google Scholar]
  • 20.Parrish, C. R. 1999. Host range relationships and the evolution of canine parvovirus. Vet. Microbiol. 69:29-40. [DOI] [PubMed] [Google Scholar]
  • 21.Parrish, C. R., C. F. Aquadro, M. L. Strassheim, J. F. Evermann, J.-Y. Sgro, and H. O. Mohammed. 1991. Rapid antigenic-type replacement and DNA sequence evolution of canine parvovirus. J. Virol. 65:6544-6552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Parrish, C. R., G. Burtonboy, and L. E. Carmichael. 1988. Characterisation of a nonhemagglutinating mutant of canine parvovirus. Virology 163:230-232. [DOI] [PubMed] [Google Scholar]
  • 23.Parrish, C. R., P. H. O'Connel, J. F. Evermann, and L. E. Carmichael. 1985. Natural variation of canine parvovirus. Science 230:1046-1048. [DOI] [PubMed] [Google Scholar]
  • 24.Pereira, C. A., T. A. Monezi, D. U. Mehnert, M. D'Angelo, and E. L. Durigon. 2000. Molecular characterisation of canine parvovirus in Brazil by polymerase chain reaction assay. Vet. Microbiol. 75:127-133. [DOI] [PubMed] [Google Scholar]
  • 25.Reed, A. P., E. V. Jones, and T. J. Miller. 1988. Nucleotide sequence and genome organization of canine parvovirus. J. Virol. 62:266-276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Sagazio, P., M. Tempesta, D. Buonavoglia, F. Cirone, and C. Buonavoglia. 1998. Antigenic characterisation of canine parvovirus strains isolated in Italy. J. Virol. Methods 73:197-200. [DOI] [PubMed] [Google Scholar]
  • 27.Simpson, A. A., V. Chandrasekar V., B. Hebert, G. M. Sullivan, M. G. Rossmann, and C. R. Parrish. 2000. Host range and variability of calcium binding by surface loops in the capsid of canine and feline parvoviruses. J. Mol. Biol. 300:597-610. [DOI] [PubMed] [Google Scholar]
  • 28.Steinel, A., E. H. Venter, M. Van Vuuren, C. R. Parrish, and U. Truyen. 1998. Antigenic and genetic analysis of canine parvoviruses in southern Africa. Ondersteeport J. Vet. Res. 65:239-242. [PubMed] [Google Scholar]
  • 29.Steinel, A., L. Munson, M. Van Vuuren, and U. Truyen. 2000. Genetic characterization of feline parvovirus sequences from various carnivores. J. Gen. Virol. 81:345-350. [DOI] [PubMed] [Google Scholar]
  • 30.Strassheim, M. L., A. Gruenberg, P. Veijalainen, J.-Y. Sgro, and C. R. Parrish. 1994. Two dominant neutralizing antigen determinants of canine parvovirus are found on the threefold spike of the virus capsid. Virology 198:175-184. [DOI] [PubMed] [Google Scholar]
  • 31.Tresnan, D. B., L. Southard, W. Weichert, J.-Y. Sgro, and C. R. Parrish. 1995. Analysis of the cell and erythrocyte binding activities of the dimple and canyon regions of the canine parvovirus capsid. Virology 211:123-132. [DOI] [PubMed] [Google Scholar]
  • 32.Truyen, U., A. Steinel, L. Bruckner, H. Lutz, and K. Mostl. 2000. Distribution of antigen types of canine parvovirus in Switzerland, Austria and Germany. Schweiz. Arch. Tierheilkd. 142:115-119. [PubMed] [Google Scholar]
  • 33.Truyen, U., A. Gruneberg, S. F. Chang, B. Obermaier, P. Veijalainen, and C. R. Parrish. 1995. Evolution of the feline-subgroup of parvoviruses and the control of canine host range in vivo. J. Virol. 69:4702-4710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Truyen, U., G. Platzer, and C. R. Parrish. 1996. Antigenic type distribution among canine parvoviruses in dogs and cats in Germany. Vet. Rec. 138:365-366. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES